Amedisys (NASDAQ:AMED) Given New $190.00 Price Target at Truist Securities

Amedisys (NASDAQ:AMED) had its price objective reduced by Truist Securities from $255.00 to $190.00 in a research report released on Wednesday morning, Price Targets.com reports. They currently have a buy rating on the health services provider’s stock.

Several other equities analysts have also issued reports on AMED. Stephens lowered their target price on shares of Amedisys from $310.00 to $237.00 and set an equal weight rating for the company in a report on Friday, August 6th. They noted that the move was a valuation call. Benchmark lowered their target price on shares of Amedisys from $325.00 to $235.00 and set a buy rating for the company in a report on Tuesday, August 10th. UBS Group assumed coverage on shares of Amedisys in a report on Thursday, September 23rd. They set a sell rating and a $150.00 target price for the company. SVB Leerink assumed coverage on shares of Amedisys in a report on Monday, September 27th. They issued a market perform rating and a $170.00 price objective for the company. Finally, Cowen assumed coverage on shares of Amedisys in a report on Thursday, September 9th. They issued a market perform rating and a $195.00 price objective for the company. One equities research analyst has rated the stock with a sell rating, six have given a hold rating and nine have assigned a buy rating to the company’s stock. According to MarketBeat, the company presently has a consensus rating of Buy and an average target price of $237.06.

Amedisys stock opened at $150.58 on Wednesday. The stock’s 50 day simple moving average is $170.56 and its two-hundred day simple moving average is $230.03. The company has a debt-to-equity ratio of 0.20, a quick ratio of 0.87 and a current ratio of 0.87. The stock has a market cap of $4.91 billion, a price-to-earnings ratio of 20.21, a PEG ratio of 2.69 and a beta of 0.51. Amedisys has a fifty-two week low of $137.82 and a fifty-two week high of $325.12.

Amedisys (NASDAQ:AMED) last posted its quarterly earnings data on Wednesday, August 4th. The health services provider reported $1.69 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $1.67 by $0.02. The business had revenue of $564.17 million for the quarter, compared to analysts’ expectations of $565.48 million. Amedisys had a return on equity of 28.55% and a net margin of 11.25%. The business’s revenue was up 16.3% on a year-over-year basis. During the same period in the previous year, the firm posted $1.34 EPS. On average, analysts predict that Amedisys will post 6.08 earnings per share for the current year.

Amedisys announced that its Board of Directors has authorized a share repurchase plan on Wednesday, August 4th that authorizes the company to buyback $100.00 million in shares. This buyback authorization authorizes the health services provider to purchase up to 1.2% of its stock through open market purchases. Stock buyback plans are often an indication that the company’s management believes its shares are undervalued.

In related news, COO Christopher Gerard sold 1,250 shares of the company’s stock in a transaction on Monday, August 2nd. The shares were sold at an average price of $261.24, for a total value of $326,550.00. Following the completion of the transaction, the chief operating officer now owns 39,006 shares of the company’s stock, valued at approximately $10,189,927.44. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, Director Bruce D. Perkins sold 11,511 shares of the company’s stock in a transaction on Wednesday, September 1st. The stock was sold at an average price of $183.00, for a total transaction of $2,106,513.00. Following the completion of the transaction, the director now directly owns 29,380 shares of the company’s stock, valued at approximately $5,376,540. The disclosure for this sale can be found here. 1.80% of the stock is currently owned by insiders.

Several hedge funds and other institutional investors have recently made changes to their positions in the company. FMR LLC raised its position in Amedisys by 13.4% in the 1st quarter. FMR LLC now owns 370,789 shares of the health services provider’s stock worth $45,703,000 after purchasing an additional 43,844 shares during the period. Teacher Retirement System of Texas raised its position in Amedisys by 22.7% in the 1st quarter. Teacher Retirement System of Texas now owns 3,624 shares of the health services provider’s stock worth $960,000 after purchasing an additional 670 shares during the period. Mercer Global Advisors Inc. ADV purchased a new stake in Amedisys in the 1st quarter worth about $396,000. Y Intercept Hong Kong Ltd purchased a new stake in Amedisys in the 1st quarter worth about $254,000. Finally, Geode Capital Management LLC raised its position in Amedisys by 5.3% in the 1st quarter. Geode Capital Management LLC now owns 441,675 shares of the health services provider’s stock worth $116,951,000 after purchasing an additional 22,383 shares during the period. Hedge funds and other institutional investors own 87.35% of the company’s stock.

About Amedisys

Amedisys, Inc engages in the provision of healthcare services. It operates through the following business segments: Home Health, Hospice, and Personal Care. The Home Health segment delivers services in the homes of individuals who may be recovering from an illness, injury, or surgery. The Hospice segment provides care that is designed to provide comfort and support for those who are facing a terminal illness.

Recommended Story: Dead Cat Bounce

Analyst Recommendations for Amedisys (NASDAQ:AMED)

Receive News & Ratings for Amedisys Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amedisys and related companies with MarketBeat.com's FREE daily email newsletter.